Jonathan W Friedberg, MD, MMSc
Leonard JP et al. Five-year results and overall survival update from the phase 3 randomized study AUGMENT: Lenalidomide plus rituximab (R2) versus rituximab plus placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2022;Abstract 230.
Morschhauser F et al. Six-year results from RELEVANCE: Lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma. J Clin Oncol 2022;40(28):3239-45. Abstract
Salles G et al. Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Updated phase 1b results of Symphony-1 with 22.5 months follow-up. ASH 2023;Abstract 3035.
Townsend W et al. Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: Final results from the GALLIUM study. HemaSphere 2023;7:e919. Abstract
Zinzani PL et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 2023;41(33):5107-19. Abstract
Jeremy S Abramson, MD, MMSc
Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Onc 2022;23(8):P1055-65. Abstract
Dreyling M et al. Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the Elara trial. ASH 2022;Abstract 608.
Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Onc 2022;23(1):P91-103. Abstract
Linton K et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: First data disclosure from the epcore NHL-1 follicular lymphoma dose-expansion cohort. ASH 2023;Abstract 1655.
Merryman R et al. Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. ASCO 2023;Abstract 7506.
Morschhauser F et al. Transcend FL: Phase 2 study results of Lisocabtagene maraleucel (liso‐cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL). ICML 2023;Abstract LBA4.
Sehn LH et al. Mosunetuzumab demonstrates durable responses in patients with relapsed and/or refractory follicular lymphoma who have received ≥2 prior therapies: Updated analysis of a pivotal phase II study. EHA 2023;Abstract P1078.
Taszner M et al. Odronextamab in patients with relapsed/refractory follicular lymphoma grade 1–3A: Results from a prespecified analysis of the pivotal phase 2 study ELM-2. EHA 2023;Abstract P1083.
Brad S Kahl, MD
Jain P et al. Acalabrutinib with rituximab as first‐line therapy for older patients with mantle cell lymphoma—A phase II clinical trial. ICML 2023;Abstract 099.
Kumar A et al. A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma. ASH 2023;Abstract 738.
Martin T et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2022;41(6):1265-74. Abstract
Ruan J at al. Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-naïve mantle cell lymphoma. ASH 2022;Abstract 73.
Villa D et al. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. Blood Adv 2022;6(18):5285-94. Abstract
Wang ML et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN Study. ASH 2022;Abstract 2884.
Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386:2482-94. Abstract
Jonathon B Cohen, MD
Hess G et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol 2022;202(4):749-59. Abstract
Le Gouill S et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica 2023;[Online ahead of print]. Abstract
Phillips TJ et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. Blood 2022;140(S1):178-80. Abstract
Song Y et al. Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. Cancer Medicine 2023;12(18):18643-53. Abstract
Wang M et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 2023;41(3):555-67. Abstract
Wang ML et al. Ibrutinib‐rituximab and venetoclax (IRV) followed by risk‐stratified R‐HYPERCVAD/MTX in young patients with untreated mantle cell lymphoma—Phase‐II WINDOW‐2 trial. ICML 2023;Abstract 101.
Wang Y et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US Lymphoma CAR T Consortium. ASH 2023;Abstract LBA-2.
Nancy L Bartlett, MD
Abramson JS et al. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Blood Adv 2023;7(7):1130-6. Abstract
Allen PB et al. Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv 2023;7:2670-76. Abstract
Annunzio K et al. Treatment patterns and outcomes for patients with classic Hodgkin Lymphoma (cHL) and cardiomyopathy with low ejection fraction (EF): Real-world evidence (RWE) from 16 US academic centers. ASH 2023;Abstract 382.
Ansell SM et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med 2022;387(4):310-20. Abstract
Bröckelmann PJ et al. Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial. J Clin Oncol 2023;41(6):1193-9. Abstract
Crosswell HE et al. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1. Haematologica 2023;[Online ahead of print]. Abstract
Evens AM et al. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study. Haematologica 2022;107(5):1086-94. Abstract
Fornecker L-M et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, phase II trial. J Clin Oncol 2023;41(2):327-55. Abstract
Friedberg JW et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy. Blood 2023;blood.2022019536. Abstract
Herrera AF et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). ASCO 2023;Abstract LBA4.
Kopmar NE et al. Toxicity profile of brexucabtagene autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in adult patients (pts) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a multicenter real-world outcomes study. ASH 2023;Abstract 522.
Lynch RC et al. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood 2023;141(21):2576-86. Abstract
Rutherford SC et al. Nivolumab-AVD is better tolerated and improves progression-free survival compared to bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826. ASH 2023;Abstract 181.
Stephen M Ansell, MD, PhD
Carlo-Stella C et al. Camidanlumab tesirine: Updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R CHL). EHA 2022;Abstract S201.
Chohan K, Ansell SM. Current salvage therapies in Hodgkin lymphoma. Leuk Lymphoma 2022;63(6):1267-80. Abstract
Lin N et al. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. Eur J Cancer 2022;164:117-26. Abstract
Nieto Y et al. Innate cell engager (ICE®) AFM13 combined with preactivated and expanded (P+E) cord blood (CB)-derived natural killer (NK) cells for patients with refractory CD30-positive lymphomas: Final results. ASH 2023;Abstract 774.
Song Y et al. Penpulimab for relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, pivotal phase I/II trial (AK105-201). Front Oncol 2022;12:925236. Abstract
Timmerman J et al. Favezelimab in combination with pembrolizumab in patients with heavily pretreated anti-PD-1–refractory classical Hodgkin lymphoma: Updated analysis of an open-label phase 1/2 study. ASH 2023;Abstract 4440.